Prosecution Insights
Last updated: November 21, 2026
Application No. 18/541,875

METHOD FOR IMMUNOSENSING ON A LIPID LAYER USING MAGNETIC TUNNEL JUNCTIONS

Non-Final OA §112§DOUBLEPATENT
Filed
Dec 15, 2023
Priority
Jun 17, 2021 — EU 21179976.2 +1 more
Examiner
LUSI, ELLIS FOLLETT
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Roche Diagnostics Operations Inc.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
49 granted / 76 resolved
+4.5% vs TC avg
Strong +54% interview lift
Without
With
+54.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
35 currently pending
Career history
113
Total Applications
across all art units

Statute-Specific Performance

§101
7.1%
-32.9% vs TC avg
§103
33.9%
-6.1% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
32.2%
-7.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 76 resolved cases

Office Action

§112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-13 and 15 are pending in the application. Claims 13 and 15 are withdrawn. Claims 1-12 are the subject of this office action. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-12 in the reply filed on 3 August 2026 is acknowledged. Claims 13 and 15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 3 August 2026. Priority The instant application is a continuation of PCT/EP2022/066366, filed 15 June 2022. The application also claims benefit of foreign application EP21179976.2, filed 17 June 2021. Information Disclosure Statement The information disclosure statements (IDS) submitted on 18 July 2024, 11 October 2024, 4 March 2025, 25 June 2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-12 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a particular embodiment of the claimed method wherein the sensor element comprises a first binding agent which is associated with an anchor layer in such a way that allows molecular movement of the first binding agent or anchoring molecule attached thereto in two dimensions within/on the anchor layer, does not reasonably provide enablement for any embodiment of a sensor element comprising “a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one magnetic label, wherein said at least one magnetic label is located within the anchor layer” as recited in claim 1(ii). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. A determination of enablement involves the consideration of the following factors: the breadth of the claims; the nature of the invention; the state of the prior art; level of one or ordinary skill; level of predictability in the art; amount of direction provided by the inventor; existence of working examples; and quantity of experimentation needed to make or use the invention based on the content of the disclosure. Regarding breadth of the claims and nature of the invention: the claims are directed to a method for determining an analyte suspected to be present in a sample comprising contacting said sample with a sensor element comprising an anchor layer and “a first binding agent which is capable of specifically binding to the analyte, which is anchored in the anchor layer and which comprises at least one magnetic label, wherein said at least one magnetic label is located within the anchor layer”. When given its broadest reasonable interpretation, these claims are understood to encompass both embodiments wherein the first binding agent is mobile/mobilizable within the anchor layer, as described in the specification (Pg. 5, Ln. 33-end) as well as embodiments wherein the first binding agent is immobilized. Though the specification provides discussion of a first binding agent that is mobile within a lipid anchoring layer, and indicates that this mobility is critical to the operability of the sensor within the claimed method, the specification does not disavow other reasonable interpretations of the claim and therefore does not limit the claim only to embodiments wherein the first binding agent is mobile over two dimensions within the anchoring layer. The broadest reasonable interpretation of a first binding agent which is anchored in an anchoring layer is therefore understood to encompass embodiments where such anchoring comprises immobilization of the first binding agent, according to the plain meaning of the terms in the art. See MPEP 2111.01(IV). Regarding state of the prior art, predictability in the art and level of one of ordinary skill: The prior art provides other examples of sandwich immunoassay sensors which comprise the use of magnetic labels and magnetic tunnel junctions. For example Wang et al (2014/0292318 A1) teaches a magnetic tunnel junction immunoassay system wherein a capture reagent is immobilized on a solid surface, wherein the reagent is capable of binding to a target analyte; a detection reagent capable of binding to the target analyte, wherein the detection reagent comprises a magnetic label; such that when target analyte is present a complex of capture antibody-analyte-detection reagent is formed, such that the amount of magnetic label in complex with the capture antibody-target analyte creates generates a detectable signal in the MTJ which is proportional to the amount of magnetic label held in proximity to the solid surface and to the amount of target analyte present in the sample. This is in contrast to the instant claim wherein the first binding agent and its associated magnetic label are explicitly anchored within the anchoring layer, and thus are present in the anchoring layer and in proximity to the solid surface regardless of whether or not the target analyte is present in the solution. In the instant case, detectable magnetic label is not removed from the solid surface when it is not bound to the target analyte. Instead, a change in signal is produced when the first binding agent and associated magnetic label are specifically held within functional proximity of the MTJ by the second binding agent in complex with the target analyte, rather than moving freely throughout the anchor layer as they would in the absence of the target analyte (Pg. 11, Ln. 35-end). As such, based on the prior art and predictability of the art, one of ordinary skill would assume that an embodiment of the instant invention wherein the first binding agent is immobilized would be inoperable, as the amount of magnetic label in proximity to the MTJ would remain fixed and constant, regardless of whether the target analyte was present in the sample. Regarding amount of direction provided by the inventor and existence of working examples: The specification specifically discusses embodiments wherein the first binding agent and its magnetic label are mobile within the anchor layer, and explicitly indicates that mobilizability of the first binding agent is crucial to the function of the sensor (Pg. 5, Ln. 33-end; Pg. 10, Ln. 33-end; Pg. 11, Ln. 35-end; Pg. 12, Ln. 34-Pg. 13, Ln. 4; Pg. 14, Ln. 15-20). Thus, as discussed above, the specification indicates that functionality of the sensor within the claimed method hinges on a mobile first binding agent which can move in two dimensions within the claimed anchor layer and is not immobilized. As such, the quantity of experimentation needed to make or use the invention based on the content of the disclosure is undue. Enablement requires that the disclosure provide a reasonable level of detail which would enable one of ordinary skill in the art to understand and carry out the invention. In the instant case, such reasonable detail is lacking. The claims are interpreted to encompass embodiments which are not enabled by the instant disclosure. That is, the language “a first binding agent…which is anchored in the anchor layer” is understood to encompass embodiments wherein said anchoring comprises immobilization of the first binding agent, and these embodiments are not enabled by the instant specification or the prior art which indicates that enablement of the claimed invention requires a mobile first binding agent. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 is rejected as indefinite over the recitation: “a second binding agent which is capable of specifically binding to the analyte when bound to the first binding agent”, wherein it is unclear whether this refers to the second binding agent bound to the first binding agent, or whether this refers to the analyte bound to the first binding agent. Clarification is required. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 9 recites the broad recitation “between 10 and 100”, and the claim also recites “between 40 and 60” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 11 recites the broad recitation “at least 100 sensor elements”, and the claim also recites “at least 100,000 sensor elements” which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Dependent claims 2-12 are rejected as indefinite because they depend from an indefinite claim and fail to remedy its deficiencies. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-5 and 7-10 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-13 of copending Application No. 18/541,476 in view of Wang et al (2014/0292318 A1). Regarding instant claim 1, all limitations of the instant claim are taught by reference claims 1, 10, and 12, with the exception the reference claim does not teach a magnetic tunnel junction, though it is noted that reference claims 11 and 13 both teach a sensor disposed below the solid support for detection of the detectable label. The reference claims are generic regarding the type of detectable label and the type of sensor used for detection. Wang teaches an immunoassay sensor for detection of an analyte in a sample which comprises first and second binding agent wherein one binding agent is immobilized on a solid support and one of the binding agent comprises a detectable label which is a magnetic label and which is detected by a MTJ sensor disposed below the solid support (Figs. 3A-3C). Wang teaches that MTJ sensors used with magnetic labels are suitable and advantageous sensor elements for the detection of a target analyte in a sample. It would have been obvious to one of ordinary skill in the art to have modified the invention of the reference claims such that the detectable label comprises a magnetic label (reference claim 10) and the sensor element comprises a MTJ. One of ordinary skill in the art would be motivated to make this modification because the reference claims are generic regarding the type of detectable label and the type of sensor element used, and one would be motivated to use a suitable label with a suitable sensor element as taught by Wang. One of ordinary skill in the art would have a reasonable expectation of success in making this modification because both the reference claims and Wang are directed to detection of analyte in a sample using systems comprising similar components. All additional limitations of instant claim 2-5, 7-10 are taught by reference claim 2-5, 7-8, 6, 9, respectively. This is a provisional nonstatutory double patenting rejection. Subject Matter Free of Prior Art Claims 1-12 are rejected as described above, but appear to contain subject matter which is free of the prior art. The closest prior art is Wang et al (2014/0292318 A1). Wang teaches a method for determining an analyte suspected to be present in a sample comprising: Contacting said sample with a sensor element (Abstract; Fig. 3A-D) comprising: A first binding agent and a second binding agent which are each capable of binding to the analyte, wherein the second binding agent is immobilized on a solid support and the first binding agent comprises a magnetic label, such that the formation of a complex of first binding agent-analyte-second binding agent generates a detectable signal at a MTJ by which the presence and concentration of analyte in the sample is determined. (Fig. 3A-D; Par. 7, 76-79). Wang differs from the instant specification in that it does not teach that the first binding is anchored in an anchor layer present on the solid support, and wherein the magnetic label is located within the anchor layer. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELLIS LUSI whose telephone number is (571)270-0694. The examiner can normally be reached M-Th 8am-6pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy Nguyen can be reached at (571) 272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ELLIS FOLLETT LUSI/Examiner, Art Unit 1677 /CHRISTOPHER L CHIN/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Dec 15, 2023
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790409
HISTAMINE BINDING POLYPEPTIDES AND USES THEREOF
3y 10m to grant Granted Nov 10, 2026
Patent 12782350
MACHINE READABLE DIAGNOSTIC TEST DEVICES AND METHODS AND APPARATUS TO MAKE AND/OR PROCESS THE SAME
3y 11m to grant Granted Nov 03, 2026
Patent 12768839
ANALYTE DETECTION USING ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY-BASED IMAGINARY IMPEDANCE MEASUREMENT
3y 10m to grant Granted Oct 20, 2026
Patent 12663424
ANTIBODY SPECIFICALLY BINDING TO WRS PROTEIN, AND USE THEREOF
4y 5m to grant Granted Jun 23, 2026
Patent 12656345
METHOD FOR DIAGNOSING HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1)-RELATED DISEASE
4y 1m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+54.1%)
3y 11m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 76 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month